secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIFECORE BIOMEDICAL, INC. DE (LFCR)
CIK:        0001005286
Form:       8-K
Filed at:   2025-01-02T23:59:59+00:00
Accession:  0001005286-25-000009
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lifecore Q2 FY25 revenue up 8% to $32.6M; net loss $6.6M on non-cash items; adj EBITDA $6.5M
--------------------------------------------------------------------------------

- Revenue $32.6M (+8% YoY); CDMO segment drove $1.9M increase, partially offset by customer mix shifts.
- Net loss of $6.6M ($0.25 diluted loss) vs prior-year net income of $14.2M which included a $20.7M non-cash gain.
- Adjusted EBITDA $6.5M, up from $5.4M YoY, driven by higher gross profit from pricing and mix.
- Completed $24.3M equity private placement and amended BMO credit facility with lower rates and 3-year extension.
- Signed new CDMO project with Nirsum Labs; installed GMP-ready 5-head isolator filler, doubling capacity to ~$300M annual revenue potential.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1005286/000100528625000009/0001005286-25-000009-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1005286/000100528625000009/lndc-20250102.htm
  HTML page:      https://secwatch.observer/filing/0001005286-25-000009

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer